Skip to main content
THE HYDRATION PHARMACEUTICALS COMPANY LIMITED logo

THE HYDRATION PHARMACEUTICALS COMPANY LIMITED — Investor Relations & Filings

Ticker · HPC ISIN · AU0000187957 ASX Manufacturing
Open in API
Filings indexed 263 across all filing types
Latest filing 2026-05-26 Major Shareholding Noti…
Country AU Australia
Listing ASX HPC

About THE HYDRATION PHARMACEUTICALS COMPANY LIMITED

https://hydralyte.com

The Hydration Pharmaceuticals Company Limited specializes in the development and distribution of oral rehydration solutions (ORS) designed to manage dehydration effectively. Operating primarily under the Hydralyte brand in North America, the company provides a range of products including effervescent tablets, powders, and ready-to-use liquids. These formulations are based on World Health Organization standards, utilizing a precise balance of electrolytes and glucose to facilitate rapid fluid absorption. The company targets consumers seeking clinical-grade hydration for various conditions such as illness, physical exertion, travel, and heat exhaustion. By focusing on scientifically backed rehydration methods, the company positions its products as a functional alternative to high-sugar sports drinks and pediatric electrolyte solutions.

Recent filings

Filing Released Lang Actions
Notice of initial substantial holder 2 pages 882.1KB
Major Shareholding Notification Classification · 96% confidence The document is a Form 603 “Notice of initial substantial holder” under the Australian Corporations Act, which details a holder crossing a reporting threshold (7.77% voting power). It clearly notifies a major shareholding change. This matches the Major Shareholding Notification category (Code: MRQ).
2026-05-26 English
Ceasing to be a substantial holder 2 pages 174.5KB
Major Shareholding Notification Classification · 94% confidence The document is an Australian Form 605 under the Corporations Act 2001, providing a formal notice of ceasing to be a substantial holder and detailing changes in relevant interests in voting securities. This is a regulatory notice of a change in significant share ownership levels. It fits the “Major Shareholding Notification” category.
2026-05-17 English
Change in substantial holding 2 pages 178.1KB
Major Shareholding Notification Classification · 98% confidence The document is a Form 604 "Notice of change of interests of substantial holder" under the Corporations Act. It reports a substantial shareholder’s change in voting power and relevant interests. It is clearly a Major Shareholding Notification rather than a financial report or other filing type.
2026-05-14 English
Reinstatement to Quotation 1 page 167.3KB
Regulatory Filings Classification · 95% confidence The document is a short market announcement from ASX Compliance dated 4 May 2026, stating that the suspension of trading in the securities of The Hydration Pharmaceuticals Company Limited will be lifted following lodgement of its Annual Report. The document does not contain the Annual Report itself, but rather announces the reinstatement to quotation contingent on the report's lodgement. The document length is only 500 characters, indicating it is an announcement rather than a full report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement related to compliance and trading status, not the Annual Report itself.
2026-05-03 English
Relodgement of Annual Report 56 pages 1.7MB
Annual Report Classification · 100% confidence The document is titled 'Annual Report For the Year Ended 31 December 2025' and contains detailed consolidated financial statements, directors' report, auditor's independence declaration, and an independent audit report. It includes comprehensive financial data, operational review, directors' information, remuneration report, and other typical components of a full annual report. The document also references the relodgement of the FY25 Annual Report due to initial mislabeling, confirming this is the full annual report itself, not just an announcement. The length of the document (15,000 characters) and the detailed financial and operational content confirm it is the actual Annual Report, not a brief announcement or certification. Therefore, the correct classification is Annual Report (10-K). FY 2025
2026-04-30 English
Q1 FY26 Quarterly Activities Report (App 4C) 9 pages 8.5MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Q1 FY26 Quarterly Report and Appendix 4C' and provides detailed financial and operational information for the quarter ended 31 March 2026. It includes quarterly net sales figures, cash flow statements, cost saving initiatives, and management commentary on performance and outlook. The presence of an Appendix 4C, which is a recognized quarterly cash flow report format under ASX Listing Rule 4.7B, further confirms this is a quarterly financial report. The document contains substantive financial data and analysis, not merely an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-04-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.